Blue Water Biotech, Inc. announced the appointment of Jay Newmark, M.D., MBA as the Company's Chief Medical Officer. Dr. Newmark is a board-certified urologist with over 30 years of experience managing Men's Health issues, including benign prostatic hyperplasia (BPH). Dr. Newmark's appointment will support Blue Water's upcoming launch of ENTADFI® and he will work closely with Blue Water management to ensure BPH patients are able to receive proper access to treatment.

In addition to his extensive medical training and experience in urology private practice, Dr. Newmark has a strong background in commercial product development in the Men's Health sector. Previously, Dr. Newmark served as Chief Medical Officer at Clarus Therapeutics, Inc., where he was integral to the launch of JATENZO® and other Men's Health initiatives. He has also worked on advanced detection technologies for prostate cancer at Genomic Health Inc. and OPKO Health Inc. Dr. Newmark received his M.D. from the University of Michigan Medical School and completed his residency in urology at the Johns Hopkins Hospital.

He also holds a Master of Business Administration from the University of Chicago.